A Nature Communications study presented engineered vesicles that improve oral antibiotic absorption while reducing gut microbiome disruption. The vesicles enhanced drug delivery across the intestinal epithelium and mitigated one of the largest limitations of oral antibiotics: off‑target microbiome damage. Authors demonstrated improved systemic exposure and preservation of key commensals in preclinical models, suggesting a formulation approach that could revive oral administration for drugs otherwise limited by poor absorption or microbiome toxicity. Clinical translation will hinge on safety, manufacturability and reproducibility of vesicle platforms.